Subscribe To
TGTX / TG Therapeutics: Would Santa Deliver An Early Present?
TGTX News
By The Motley Fool
November 1, 2023
Why TG Therapeutics Stock Is Crushing It Today
The company reported Q3 results that were much better than expected. An up-front licensing payment from Neuraxpharm was a big factor in these surprisi more_horizontal
By Schaeffers Research
November 1, 2023
Biopharmaceutical Stock Soars on Earnings Beat
TG Therapeutics Inc (NASDAQ:TGTX) stock is soaring today, after the biopharmaceutical name's third-quarter results smashed analyst expectations. more_horizontal
By Seeking Alpha
October 16, 2023
TG Therapeutics: Things Are Stacking Up Against Briumvi
TG Therapeutics, Inc. stock has declined by 75% since its approval highs, with little hope of recovery. The company's fortunes have been tied to its e more_horizontal
By Invezz
October 11, 2023
TG Therapeutics (TGTX) stock price has plunged: buy the dip?
TG Therapeutics (NASDAQ: TGTX) stock price sell-off continued this week as concerns about the rising competition continued. The shares plunged to a lo more_horizontal
By Seeking Alpha
October 3, 2023
TG Therapeutics: Racing Against Time While Their Differentiators Are Still Relevant
TG Therapeutics has transitioned from a developer of oncology drugs to a commercial-stage neurology company with the approval of its multiple sclerosi more_horizontal
By GlobeNewsWire
September 22, 2023
TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
Fireside chat scheduled for Tuesday, September 26, 2023, at 12:25 PM ET Fireside chat scheduled for Tuesday, September 26, 2023, at 12:25 PM ET more_horizontal
By InvestorPlace
August 1, 2023
Why Is TG Therapeutics (TGTX) Stock Down 50% Today?
Following a disappointing outcome for the second quarter, shares of biotechnology firm TG Therapeutics (NASDAQ: TGTX ) suffered a catastrophic loss. S more_horizontal
By Seeking Alpha
July 29, 2023
TG Therapeutics: Addressing The SC Ocrevus Concern
The launch of Briumvi is off to a solid start, but the stock pulled back recently and fell more after Roche reported positive phase 3 results of subcu more_horizontal